ReviewEJNMMI radiopharmacy and chemistry2018
Production of novel diagnostic radionuclides in small medical cyclotrons.
Review in EJNMMI radiopharmacy and chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Rethinking the concept of disease modification in an evolving Parkinson's disease treatment landscape.Journal of Parkinson's disease · 2026Review
- Carbon-11 Production: Communication, Operations, Maintenance, Troubleshooting, and Analysis for Maintaining High-Grade Bombardment and Provisions of [Molecules (Basel, Switzerland) · 2026Article
- Monte Carlo prediction and experimental characterisation of long-lived waste byproducts arising from cyclotron production of zirconium-89 utilising a commercially available yttrium foil.Physical and engineering sciences in medicine · 2025Article
- Prostate Cancer Imaging Beyond PSMA: Applications of GRPR, AR, and Amino Acid Tracers.Diagnostics (Basel, Switzerland) · 2025Review
- Translating lifestyle interventions for optimal brain health in Africa.Nature reviews. Neurology · 2025Review
- Nanoradiopharmaceuticals: Design Principles, Radiolabeling Strategies, and Biomedicine Applications.Pharmaceutics · 2025Review
- Production and Supply of Raw Materials for Radiometals used in Radionuclide Imaging and Therapy in Korea.Nuclear medicine and molecular imaging · 2025Review
- Quantitative assessment ofRadiological physics and technology · 2025Article
- The Environmental Impact of Medical Imaging Agents and the Roadmap to Sustainable Medical Imaging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Novel radionuclides: demand, production and distribution for translational research in Europe.EJNMMI radiopharmacy and chemistry · 2024Review
- Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues.International journal of molecular sciences · 2024Review
- Scandium Radioisotopes-Toward New Targets and Imaging Modalities.Molecules (Basel, Switzerland) · 2023Review
- Current State ofCurrent radiopharmaceuticals · 2023Review
- Cyclotron Production of Gallium-68 Radiopharmaceuticals Using thePharmaceutics · 2022Review
- Synthesis of Radioiodinated Compounds. Classical Approaches and Achievements of Recent Years.International journal of molecular sciences · 2022Review
- Preparation and Evaluation of [Molecules (Basel, Switzerland) · 2022Article
- Production Review of Accelerator-Based Medical Isotopes.Molecules (Basel, Switzerland) · 2022Review
- Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.European journal of nuclear medicine and molecular imaging · 2022Article
- Efficiency ofEJNMMI physics · 2022Article
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board.EJNMMI radiopharmacy and chemistry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global network of cyclotrons has expanded rapidly over the last decade. The bulk of its industrial potential is composed of small medical cyclotrons with a proton energy below 20 MeV for radionuclides production. This review focuses on the recent developments of novel medical radionuclides produced by cyclotrons in the energy range of 3 MeV to 20 MeV. The production of the following medical radionuclides will be described based on available literature sources: Tc-99 m, I-123, I-124, Zr-89, Cu-64, Ga-67, Ga-68, In-111, Y-86 and Sc-44. Remarkable developments in the production process have been observed in only some cases. More research is needed to make novel radionuclide cyclotron production available for the medical industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.